Clinical trials: Pioglitazone
Type 2 Diabetes Mellitus
A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator
The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.
- Trial name
- NCT00760578
- Testing
- Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg
- Where
- 8 sites in United States
- Volunteers
- 86 people
- Sponsor
- Metabolic Solutions Development Company
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment.
- Trial name
- NCT00736099
- Testing
- linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg
- Where
- 232 sites in United States, Argentina and 30 more
- Volunteers
- 2,122 people
- Sponsor
- Boehringer Ingelheim
Obesity, Overweight With Indications for Weight Loss
Optimizing Body Composition for Function in Older Adults
The purpose of this pilot study is to compare two strategies intended to improve the health of overweight older adults by improving body composition.
- Trial name
- NCT00315146
- Testing
- Pioglitazone, Resistance exercise training to maximize muscle power, Hypocaloric diet
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Type 2 Diabetes Mellitus
A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
The purpose of this study is to compare insulin peglispro (LY2605541) to insulin glargine in Asian insulin naïve participants who have been treated with oral anti hyperglycemia medications.
- Trial name
- NCT01894568
- Testing
- Insulin Peglispro, Insulin Glargine, Oral Antihyperglycemic Medications (OAMs)
- Where
- 31 sites in Japan, South Korea and 1 more
- Volunteers
- 388 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
A 30-week extension to a 24-week study assessing the hemoglobin A1c (HbA1c)- and fasting plasma glucose (FPG)-lowering efficacy of the combination of sitagliptin and pioglitazone in patients with type 2 diabetes mellitus (T2DM)…
- Trial name
- NCT01028391
- Testing
- Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d., Metformin
- Volunteers
- 317 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Pharmacogenomics of Thiazolidinediones
The purpose of this study is to determine predictors of response to pioglitazone, an anti-diabetic medication. The investigators know from randomized clinical trials that some 30% of patients do not respond to this type of…
- Trial name
- PPAR (NCT01135394)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
- Trial name
- NCT00839527
- Testing
- albiglutide, metformin, glimepiride
- Where
- 358 sites in United States, Germany and 7 more
- Volunteers
- 685 people
- Sponsor
- GlaxoSmithKline
Hepatitis
Treating Nonalcoholic Steatohepatitis With Pioglitazone
Nonalcoholic steatohepatitis (NASH) is a common liver disease that resembles alcoholic hepatitis but occurs in persons who drink little or no alcohol.
- Trial name
- NCT00062764
- Testing
- Actos (Pioglitazone)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nonalcoholic Steatohepatitis
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition frequently associated with type 2 diabetes (T2DM) and characterized by insulin resistance and hepatic fat accumulation.
- Trial name
- VA NASH (NCT01002547)
- Testing
- pioglitazone, Vitamin E
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- VA Office of Research and Development
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
This study will examine the safety and efficacy of the addition of omarigliptin in Japanese participants with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic agent…
- Trial name
- NCT01697592
- Testing
- Omarigliptin
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer, Endobronchial Dysplasia
Pioglitazone for Lung Cancer Chemoprevention
This is a chemoprevention trial evaluating the diabetic agent pioglitazone. Non-diabetic subjects at risk for lung cancer (based on smoking history, lung function testing, and atypical cells in a sputum sample) receive either…
- Trial name
- NCT00780234
- Testing
- fluorescence bronchoscopy, quantitative high resolution CT scan
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- VA Office of Research and Development
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes.
- Trial name
- AWARD-1 (NCT01064687)
- Testing
- LY2189265, Exenatide, Metformin
- Where
- 89 sites in United States, Argentina and 2 more
- Volunteers
- 978 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major, Metabolic Syndrome X
Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome
The goal of this study is to begin to test whether or not pioglitazone, an FDA approved medication used to treat high blood sugar, may be safe and effective in treating Major Depressive Disorder (MDD) in patients with comorbid…
- Trial name
- NCT00671515
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Joseph Calabrese, MD
Diabetes Mellitus, Type 2
Thiazolidinedione Intervention With Vitamin D Evaluation
This study will answer two separate questions. The first question is to test the cardiovascular effects of long-term treatment with rosiglitazone or pioglitazone when used as part of standard of care compared to similar standard…
- Trial name
- TIDE (NCT00879970)
- Testing
- pioglitazone, rosiglitazone, Vitamin D
- Where
- 331 sites in United States, Argentina and 23 more
- Volunteers
- 1,332 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus
Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.
The purpose of this study is to compare the efficacy of Alogliptin, once daily (QD), taken by itself and with pioglitazone on postprandial lipid measures in type 2 diabetes.
- Trial name
- NCT00655863
- Testing
- Alogliptin and Pioglitazone, Alogliptin
- Where
- 2 sites in Netherlands, Sweden
- Volunteers
- 71 people
- Sponsor
- Takeda
Metabolic Syndrome
Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL
We will test our primary hypothesis that combining niacin extended release (niacin-ER), at a daily dosage of up to 2.0 g with pioglitazone, at a daily dosage of 45 mg will result in a 12% greater increase in HDL-C when compared…
- Trial name
- NCT00300365
- Testing
- Pioglitazone, Niacin ER, Aspirin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Pennsylvania
Type 2 Diabetes Mellitus (T2DM)
Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)
A clinical study to determine the safety, efficacy and mechanism of action of sitagliptin alone and in combination with pioglitazone, in patients with type 2 diabetes mellitus who have inadequate glycemic (blood sugar) control.
- Trial name
- NCT00511108
- Testing
- Comparator: sitagliptin phosphate, Comparator: pioglitazone
- Volunteers
- 211 people
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment Due to Alzheimer's Disease
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
The purpose of this study is to evaluate the effect of pioglitazone at 24 months compared with placebo on cognitive decline in high-risk participants who have completed the AD-4833/TOMM40_301 study [NCT01931566] with an…
- Trial name
- NCT02284906
- Testing
- Pioglitazone
- Where
- 43 sites in United States, Australia and 2 more
- Volunteers
- 40 people
- Sponsor
- Takeda
Metabolic Syndrome, Insulin Resistance
Mechanisms Underlying Metabolic Syndrome in Obesity
The purpose of this study is to better understand the link between obesity and diabetes or pre-diabetes.
- Conditions
- Metabolic Syndrome, Insulin Resistance, Prediabetes
- Trial name
- NCT00579813
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Philip Kern
Type 2 Diabetes
Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and efficacy of long-term use of Sonias Combination Tablets in patients with type 2 diabetes mellitus in the routine clinical setting.
- Trial name
- NCT02098733
- Testing
- Pioglitazone/glimepiride
- Volunteers
- 1,168 people
- Sponsor
- Takeda